恩替卡韦联合苦参素片治疗慢性乙型肝炎41例

目的:评价恩替卡韦联合苦参素片治疗慢性乙型肝炎(CHB)的疗效和安全性。方法:81例CHB患者分为治疗组(A组)和对照组(B组)。A组予恩替卡韦0.15mg口服,1次/d;苦参素片0.2g口服,3次/d。B组予干扰素α-2b3MU,肌肉注射,隔日1次。结果:A组治疗8周时HBV-DNA水平较治疗前显著下降;治疗12周,HBV-DNA阴转率为21.9%、HBeAg阴转率为37.5%,显著优于对照组;治疗24周,HBV-DNA阴转率为46.3%、HBeAg阴转率为48.78%,与对照组比较及治疗组自身比较差异显著,肝功能复常率为92.68%。治疗过程中未发生与观察药物相关的不良反应。结论:恩替卡韦联合应用苦参素片能快速、强效地抑制乙型肝炎病毒复制,安全性和耐受性良好。

Early results of entecavir associated with kushenin to treat chronicity type B hepatitis of 41 patients

Objective：To summarise curative effect and safety of entecavir associated with kushenin to treat chronicity type B hepatitis. Methods ：81 patients with chronicity type B hepatitis were divided into two groups, therapy group （A group） and control group （B group）. A group was treated by entecavir 0.15rag for oral use once a day and kushenin 0.2 g for oral use three times a day. B group was treated byα-2b interferon 3MU intramuscular injection once every other day. Results ：HBV- DNA level decreased obviously 8 weeks later in A group. Rate of became negative for HBV-DNA was 21. 9% and HbeAg was 37. 5% after 12 weeks later and curative effect was significant better than control group. Rate of became negative for HBV-DNA was 46. 3% and HbeAg was 48. 78% after 24 weeks later and diffierence was significant between control group and therapy group . Rate for liver function became normal was 92.68% and means having better responder reaction. There was no adverse effect related with observe medicine. Conclusion： Enteeavir associated with kushenin could fast and strong inhibit hepatitis B virus copying. Safety and toleration is good.